We conducted a phase 3, open-label, pragmatic, randomized, controlled noninferiority trial in South Africa to assess a 6-month treatment strategy for pulmonary rifampicin-resistant tuberculosis.
The new antibiotic screening system proposed by the authors of the study proved to be sensitive to both fidaxomicin and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results